Aspire Biopharma, Inc. (NASDAQ:PWUP) | WebDisclosure

Switch to English

11281	Sociétés
250666	Mots-clés
179342	Articles
136487	Communiqués

Accueil
Sociétés
Aspire Biopharma, Inc.

COMMUNIQUÉ DE PRESSE

publié le 10/06/2025 à 14:30, il y a 1 année 4 mois

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 1 année 5 mois

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 1 année 5 mois

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
COMMUNIQUÉ DE PRESSE

publié le 28/05/2025 à 14:30, il y a 1 année 5 mois

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 1 année 5 mois

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 1 année 5 mois

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
COMMUNIQUÉ DE PRESSE

publié le 20/05/2025 à 14:30, il y a 1 année 5 mois

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 1 année 5 mois

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 1 année 5 mois

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
COMMUNIQUÉ DE PRESSE

publié le 08/05/2025 à 14:00, il y a 1 année 5 mois

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Les Echos

Publié le 05/11/2026 à 07:44, il y a 29 minutes

Résultats d’ENGIE 9 mois 2026
Publié le 05/11/2026 à 07:44, il y a 29 minutes

ENGIE 9M 2026 results
Publié le 05/11/2026 à 07:00, il y a 1 heure 14 minutes

Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Publié le 05/11/2026 à 07:00, il y a 1 heure 14 minutes

Eurazeo’s European asset management platform continues to gain momentum, driven by sustained international fundraising
Publié le 05/11/2026 à 07:00, il y a 1 heure 14 minutes

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/11/2026 à 08:00, il y a 14 minutes

Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
Publié le 04/11/2026 à 23:10, il y a 9 heures 4 minutes

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Publié le 04/11/2026 à 23:00, il y a 9 heures 14 minutes

Avino Reports Q3 2026 Financial Results
Publié le 04/11/2026 à 23:00, il y a 9 heures 14 minutes

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Publié le 04/11/2026 à 22:15, il y a 9 heures 59 minutes

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Voir tout ACCESSWIRE

EQS Group

Publié le 05/11/2026 à 08:07, il y a 6 minutes

Leifheit AG publishes its Q3 2026 quarterly statement and accelerates the FOCUS performance program
Publié le 05/11/2026 à 08:00, il y a 13 minutes

Ørsted delivers strong earnings with 19 % EBITDA growth, and offshore wind farms Borkum Riffgrund 3 in Germany and Revolution Wind in the US reach commercial operations
Publié le 05/11/2026 à 08:00, il y a 14 minutes

Cairn Homes Plc: Transaction in Own Shares
Publié le 05/11/2026 à 08:00, il y a 14 minutes

Portfolio update and Notice of Results
Publié le 05/11/2026 à 08:00, il y a 14 minutes

Nine months of 2026: 11880 Solutions AG increases EBITDA and strengthens the foundation for future growth